A new study confirms that Theranica’s Nerivio REN wearable for migraine can be used safely alongside the most common continuous glucose monitoring (CGM) devices without impacting glucose readings.

Published in the Journal of Clinical Medicine, the interventional single-arm compatibility study evaluated 21 adults with diabetes using CGM systems concurrently with a 45-minute Nerivio session. Devices tested included Abbott FreeStyle Libre 2 and 3 and Dexcom G6 and G7. Researchers compared glucose measurements during active REN stimulation to those taken when stimulation was paused.

Results showed a median deviation of just 1.6%, well below the study’s 5% mean absolute relative difference (MADR) threshold. Abbott FreeStyle Libre users showed a median deviation of 1.0%, while Dexcom users showed 1.7%. No Bluetooth interference, missed transmissions, device malfunctions, or adverse events were observed. Data capture remained complete, confirming stable operation of both Nerivio and CGM devices during simultaneous use.

“This demonstrates that the Nerivio REN wearable and CGM systems can be used together without compromising glucose data integrity — which is critically important for people managing both migraine and diabetes,” said Christina Treppendahl, certified headache medicine specialist and medical science liaison at Theranica, who co-authored the study. “Many people living with migraine are also managing other chronic conditions. They rely on multiple connected health technologies every day. Our goal is not only to provide effective drug-free migraine treatment, but to ensure our technology integrates safely into patients’ broader care ecosystems.”

Migraine and diabetes affect millions globally. In the United States alone, an estimated 4.5 million people live with both conditions, highlighting the importance of safe, compatible treatment strategies.

Nerivio is a drug-free, FDA-cleared wearable that delivers migraine therapy through remote electrical neuromodulation (REN) and is controlled via a smartphone app. The study is the first to directly evaluate the concurrent use of a neuromodulation migraine therapy with CGM devices, addressing questions raised by patients and healthcare providers about safety in real-world care.

Dr. Richelle deMayo, chief medical information officer at Connecticut Children’s Research Institute, said: “Migraine treatment can be especially complex for individuals with diabetes because many pharmacologic options carry metabolic or cardiovascular considerations. As connected health technologies continue to expand, confirming safe multi-device operation is increasingly important for real-world patient care.”

The study provides reassurance that Nerivio can be safely integrated into broader chronic care management, supporting patients who rely on multiple connected health devices.